Kazia Therapeutics Limited
KZIANASDAQHealthcare● Active
$11.40
+$0.41(+3.73%)
Market Cap$18465617
P/E Ratio—
52W High$17.4
52W Low$4.86
Kazia Therapeutics Limited (KZIA) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
KZIA · earnings · updated Jun 8, 2026
Latest Earnings
Q1 FY2026Report Date: Mar 16, 2026EPS Actual
-$0.58
Est. -$0.01 · -8205.2%
Revenue
$0.00B
Fiscal Period
Q1 FY2026
FY ends December
Report Date
Mar 16, 2026
After Market Close
▼ Miss EPS
KZIA reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.09
Rev. $41.31B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.09
Rev. Est.$41.31B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Sep 4, 2026 | -$0.70 | — | — | — | $0.00B | — |
| ▼ Q1 FY2026 | Mar 16, 2026 | -$0.01 | -$0.58 | -8205.2% | $0.00B | — | — |
| ▼ Q2 FY2025 | Jun 30, 2025 | -$0.01 | -$4.18 | -63968.6% | $0.00B | $0.00B | +23.2% |
| ▲ Q2 FY2025 | May 28, 2025 | -$10.76 | -$7.61 | +29.3% | $0.00B | — | — |
| ▼ Q4 FY2024 | Nov 19, 2024 | -$15.00 | -$20.81 | -38.8% | $0.00B | $0.00B | +1554.2% |
| — Q1 FY2024 | Mar 27, 2024 | — | -$12.53 | — | $0.00B | — | — |
| ▼ Q4 FY2023 | Nov 27, 2023 | -$1.66 | -$10.02 | -504.8% | $0.00B | — | — |
| ▼ Q1 FY2023 | Mar 9, 2023 | -$24.65 | -$31.86 | -29.3% | — | $0.00B | — |
Q3 FY2026
Sep 4, 2026
EPS Actual
—
EPS Est.
-$0.70
EPS Surpr.
—
Revenue
—
Q1 FY2026
Mar 16, 2026Miss
EPS Actual
-$0.58
EPS Est.
-$0.01
EPS Surpr.
-8205.2%
Revenue
$0.00B
Q2 FY2025
Jun 30, 2025Miss
EPS Actual
-$4.18
EPS Est.
-$0.01
EPS Surpr.
-63968.6%
Revenue
$0.00B
Q2 FY2025
May 28, 2025Beat
EPS Actual
-$7.61
EPS Est.
-$10.76
EPS Surpr.
+29.3%
Revenue
$0.00B
Q4 FY2024
Nov 19, 2024Miss
EPS Actual
-$20.81
EPS Est.
-$15.00
EPS Surpr.
-38.8%
Revenue
$0.00B
Q1 FY2024
Mar 27, 2024
EPS Actual
-$12.53
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q4 FY2023
Nov 27, 2023Miss
EPS Actual
-$10.02
EPS Est.
-$1.66
EPS Surpr.
-504.8%
Revenue
$0.00B
Q1 FY2023
Mar 9, 2023Miss
EPS Actual
-$31.86
EPS Est.
-$24.65
EPS Surpr.
-29.3%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $0.00 | $0.00 | $0.00 | 0 |
| Q3 FY2025 | $0.00 | $0.00 | $0.00 | 0 |
| Q2 FY2025 | $-0.01 | $-0.01 | $-0.01 | 1 |
| Q2 FY2024 | $-0.45 | $-0.45 | $-0.45 | 1 |
| Q2 FY2023 | $0.00 | $0.00 | $0.00 | 0 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2023 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q1 FY2026 | Mar 16, 2026 | -8205.2% | $7.49 | $8.11 | +8.28% |
| ▼ Q2 FY2025 | Jun 30, 2025 | -63968.6% | $6.34 | $6.27 | -1.10% |
| ▲ Q2 FY2025 | May 28, 2025 | +29.3% | $3.74 | $3.56 | -4.81% |
| ▼ Q4 FY2024 | Nov 19, 2024 | -38.8% | $25.40 | $28.55 | +12.40% |
| — Q1 FY2024 | Mar 27, 2024 | — | $15.78 | $15.69 | -0.57% |
| ▼ Q4 FY2023 | Nov 27, 2023 | -504.8% | $35.00 | $29.90 | -14.57% |
| ▼ Q1 FY2023 | Mar 9, 2023 | -29.3% | $51.50 | $50.88 | -1.20% |
| — Q4 FY2022 | Oct 6, 2022 | — | $61.00 | $54.00 | -11.48% |
Q1 FY2026+8.28%
Report Date
Mar 16, 2026
EPS Beat/Miss
-8205.2%
Price Before
$7.49
Price After
$8.11
Q2 FY2025-1.10%
Report Date
Jun 30, 2025
EPS Beat/Miss
-63968.6%
Price Before
$6.34
Price After
$6.27
Q2 FY2025-4.81%
Report Date
May 28, 2025
EPS Beat/Miss
+29.3%
Price Before
$3.74
Price After
$3.56
Q4 FY2024+12.40%
Report Date
Nov 19, 2024
EPS Beat/Miss
-38.8%
Price Before
$25.40
Price After
$28.55
Q1 FY2024-0.57%
Report Date
Mar 27, 2024
EPS Beat/Miss
—
Price Before
$15.78
Price After
$15.69
Q4 FY2023-14.57%
Report Date
Nov 27, 2023
EPS Beat/Miss
-504.8%
Price Before
$35.00
Price After
$29.90
Q1 FY2023-1.20%
Report Date
Mar 9, 2023
EPS Beat/Miss
-29.3%
Price Before
$51.50
Price After
$50.88
Q4 FY2022-11.48%
Report Date
Oct 6, 2022
EPS Beat/Miss
—
Price Before
$61.00
Price After
$54.00
Avg Beat Reaction-4.81%
Avg Miss Reaction+0.76%
Beat Rate1 / 8 quarters
Largest Move-14.57% (Q4 FY2023)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: KZIA ends December
Kazia Therapeutics Limited (KZIA) most recently reported earnings on March 16, 2026 for Q1 FY2026, posting EPS of $-0.58 — missing the analyst consensus of $-0.01 by -8205.2%. The next KZIA earnings date is expected around September 1, 2026.
Each quarter, investors track KZIA earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. KZIA revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
KZIA's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
KZIA earnings · 5 questionsKazia Therapeutics Limited's next earnings report is expected around September 1, 2026. KZIA typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; KZIA historically reports after market close (AMC).
KZIA earnings datewhen is KZIA earningsKZIA next earnings datewhen does KZIA report earningsKZIA earnings calendar
▸ Source: FMP · Kazia Therapeutics Limited SEC filings · US GAAP · Kazia Therapeutics Limited SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026